Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.
The further development of allosteric HIV-1 RT inhibitors in the urea analogue series of PETT (phenylethylthiazolylthiourea) derivatives is described here. The series includes derivatives with an ethyl linker (1-5) and racemic (6-16) and enantiomeric (17-20) cis-cyclopropane compounds. The antiviral activity was determined both at the RT level and in cell culture on both wild-type and mutant forms of HIV-1. Most compounds have anti-HIV-1 activity on the wt in the nanomolar range. Resistant HIV-1 was selected in vitro for some of the compounds, and the time for resistant HIV-1 to develop was longer for urea-PETT compounds than it was for reference compounds. Preliminary pharmacokinetics in rats showed that compound 18 is orally bioavailable and penetrates well into the brain. The three-dimensional structure of complexes between HIV-1 RT and two enantiomeric compounds (17 and 18) have been determined. The structures show similar binding in the NNI binding pocket. The propionylphenyl moieties of both inhibitors show perfect stacking to tyrosine residues 181 and 188. The cyclopropyl moiety of the (+)-enantiomer 18 exhibits optimal packing distances for the interactions with leucine residue 100 and valine residue 179.
Högberg
M
M
Medivir AB, Lunastigen 7, S-141 44 Huddinge, Sweden.
Sahlberg
C
C
Engelhardt
P
P
Noréen
R
R
Kangasmetsä
J
J
Johansson
N G
NG
Oberg
B
B
Vrang
L
L
Zhang
H
H
Sahlberg
B L
BL
Unge
T
T
Lövgren
S
S
Fridborg
K
K
Bäckbro
K
K
D000284:Administration, Oral; D000631:Aminopyridines / Q000138:chemical synthesis* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D000818:Animals; D019380:Anti-HIV Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D001682:Biological Availability; D018360:Crystallography, X-Ray; D004352:Drug Resistance, Microbial; D015497:HIV-1 / Q000201:enzymology*; D007275:Injections, Intravenous; D008297:Male; D008958:Models, Molecular; D008968:Molecular Conformation; D051381:Rats; D018894:Reverse Transcriptase Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D014508:Urea / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology
D000631:Aminopyridines; D019380:Anti-HIV Agents; C122061:N-(2-(6-fluoro-2-hydroxy-3-propionylphenyl)cyclopropyl)-N'-(2-(5-bromopyridyl))urea; D018894:Reverse Transcriptase Inhibitors; D014508:Urea